CureVac (NASDAQ:CVAC) Shares Gap Up – Here’s Why

CureVac (NASDAQ:CVAC)’s share price gapped up before the market opened on Monday . The stock had previously closed at $3.62, but opened at $4.14. CureVac shares last traded at $4.07, with a volume of 388,877 shares trading hands.

Wall Street Analyst Weigh In

Separately, JMP Securities reiterated a “market outperform” rating and set a $16.00 target price on shares of CureVac in a research note on Monday, September 16th.

CureVac Stock Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The company has a market cap of $1.05 billion, a PE ratio of 8.51, a price-to-earnings-growth ratio of 0.24 and a beta of 2.50. The company’s 50 day moving average price is $3.00 and its 200-day moving average price is $3.13.

Institutional Trading of CureVac

A number of large investors have recently bought and sold shares of CVAC. Private Advisor Group LLC bought a new position in shares of CureVac during the 3rd quarter worth $30,000. International Assets Investment Management LLC purchased a new stake in CureVac during the third quarter valued at about $35,000. Integrated Wealth Concepts LLC bought a new position in CureVac during the third quarter worth about $35,000. Bank of New York Mellon Corp purchased a new position in shares of CureVac in the second quarter worth about $54,000. Finally, Barclays PLC bought a new stake in shares of CureVac in the third quarter valued at approximately $67,000. 17.26% of the stock is owned by hedge funds and other institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.